Atlas Venture Associates Opportunity I, LLC's Net Worth
$481 Million
Who is Atlas Venture Associates Opportunity I, LLC?
Atlas Venture Associates Opportunity I, LLC has an estimated net worth of $481 Million. This is based on reported shares across multiple companies, which include Vigil Neuroscience, Inc., Day One Biopharmaceuticals, Inc., Dyne Therapeutics, Inc., Generation Bio Co., Akero Therapeutics, Inc., Replimune Group, Inc., Ikena Oncology, Inc., Kymera Therapeutics, Inc., Magenta Therapeutics, Inc., Disc Medicine, Inc., Xilio Therapeutics, Inc., AVROBIO, Inc., and Third Harmonic Bio, Inc..
SEC CIK
Atlas Venture Associates Opportunity I, LLC's CIK is 0001780066
Past Insider Trading and Trends
2022 was Atlas Venture Associates Opportunity I, LLC's most active year for acquiring shares with 10 total transactions. Atlas Venture Associates Opportunity I, LLC's most active month to acquire stocks was the month of May. 2021 was Atlas Venture Associates Opportunity I, LLC's most active year for disposing of shares, totalling 38 transactions. Atlas Venture Associates Opportunity I, LLC's most active month to dispose stocks was the month of November. 2022 saw Atlas Venture Associates Opportunity I, LLC paying a total of $34,090,021.70 for 16,180,239 shares, this is the most they've acquired in one year. In 2023 Atlas Venture Associates Opportunity I, LLC cashed out on 675,637 shares for a total of $34,351,525.03, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Day One Biopharmaceuticals, Inc. (DAWN) Snapshot price: $15.83
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 766.67K |
$15.00 | $11,500,005.00 | 766.67K |
Jun 17
| |||
Form 4
|
∞
| 9M |
$16.00 | $8,000,000.00 | 9M |
Feb 1 - Jun 1
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
Dyne Therapeutics, Inc. (DYN) Snapshot price: $21.5
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
| -1.98% | -46.53K |
$30.05 | -$1,398,346.70 | 2.31M |
Scheduled
|
Mar 1
| ||
Form 4
| -5.89% | -807.84K |
$24.32 | -$19,626,902.97 | 12.9M |
Scheduled
|
Feb 26 - Feb 28
| ||
Form 4
| -5.35% | -500.79K |
$22.68 | -$11,339,780.44 | 8.86M |
Scheduled
|
Feb 21 - Feb 23
| ||
Form 4
|
∞
| 934.58K |
$10.70 | $10,000,016.70 | 934.58K |
Dec 12
| |||
Form 4
| +361.95% | 7.64M |
—
|
—
| 9.75M |
Sep 21
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
Akero Therapeutics, Inc. (AKRO) Snapshot price: $17.88
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 3.97M |
$16.00 |
—
| 3.97M |
Jun 24
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
Ikena Oncology, Inc. (IKNA) Snapshot price: $1.43
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
| +4.89% | 98.72K |
$15.34 | $1,614,428.13 | 2.12M |
Mar 30 - Dec 14
| |||
Form 4
| +2,809.29% | 4.75M |
—
|
—
| 4.92M |
Mar 30
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
Xilio Therapeutics, Inc. (XLO) Snapshot price: $0.6453
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
| -0.04% | -1.00K |
$0.64 | -$640.00 | 2.75M |
Feb 8
| |||
Form 4
| -0.15% | -4.24K |
$0.85 | -$3,600.45 | 2.76M |
Jan 11 - Jan 12
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |